Hologic, Inc. (NASDAQ:HOLX) Receives $79.29 Consensus PT from Analysts

Hologic, Inc. (NASDAQ:HOLX) has received an average rating of “Hold” from the eighteen research firms that are currently covering the stock, Marketbeat reports. Fourteen research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 12-month price objective among analysts that have covered the stock in the last year is $79.2857.

Several research firms have recently weighed in on HOLX. BTIG Research restated a “neutral” rating on shares of Hologic in a research note on Tuesday, October 21st. Mizuho downgraded Hologic from an “outperform” rating to a “neutral” rating and boosted their price target for the stock from $70.00 to $78.00 in a research report on Thursday, October 23rd. BNP Paribas Exane cut Hologic from an “outperform” rating to a “neutral” rating and set a $79.00 price objective for the company. in a research report on Friday, November 21st. JPMorgan Chase & Co. reiterated a “neutral” rating and set a $78.00 target price on shares of Hologic in a research note on Wednesday, October 22nd. Finally, Stephens cut Hologic from an “overweight” rating to an “equal weight” rating and dropped their price target for the company from $78.00 to $76.00 in a research note on Wednesday, October 22nd.

Hologic Stock Up 0.3%

NASDAQ:HOLX opened at $74.75 on Thursday. Hologic has a twelve month low of $51.90 and a twelve month high of $75.34. The firm has a market capitalization of $16.66 billion, a price-to-earnings ratio of 30.14, a price-to-earnings-growth ratio of 2.12 and a beta of 0.69. The company has a quick ratio of 3.06, a current ratio of 3.75 and a debt-to-equity ratio of 0.50. The stock’s 50 day moving average price is $74.57 and its two-hundred day moving average price is $69.60.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Monday, November 3rd. The medical equipment provider reported $1.13 EPS for the quarter, beating the consensus estimate of $1.10 by $0.03. The company had revenue of $1.05 billion during the quarter, compared to the consensus estimate of $1.03 billion. Hologic had a return on equity of 20.13% and a net margin of 13.80%.The firm’s revenue for the quarter was up 6.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.01 EPS. Equities research analysts expect that Hologic will post 4.28 earnings per share for the current fiscal year.

Insider Buying and Selling at Hologic

In other news, Director Christiana Stamoulis sold 7,402 shares of the firm’s stock in a transaction dated Monday, October 20th. The shares were sold at an average price of $73.07, for a total transaction of $540,864.14. Following the completion of the sale, the director owned 47,336 shares in the company, valued at approximately $3,458,841.52. This trade represents a 13.52% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 1.88% of the stock is owned by insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. The Manufacturers Life Insurance Company boosted its holdings in shares of Hologic by 294.3% during the second quarter. The Manufacturers Life Insurance Company now owns 11,022,455 shares of the medical equipment provider’s stock worth $718,223,000 after acquiring an additional 8,227,318 shares during the period. Invesco Ltd. lifted its holdings in Hologic by 72.5% during the 2nd quarter. Invesco Ltd. now owns 8,340,785 shares of the medical equipment provider’s stock worth $543,486,000 after purchasing an additional 3,505,828 shares during the last quarter. Norges Bank bought a new stake in Hologic in the 2nd quarter valued at $180,055,000. Allspring Global Investments Holdings LLC boosted its stake in Hologic by 473.5% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 1,701,820 shares of the medical equipment provider’s stock valued at $111,180,000 after purchasing an additional 1,405,085 shares during the period. Finally, Balyasny Asset Management L.P. grew its holdings in Hologic by 1,060.1% in the 3rd quarter. Balyasny Asset Management L.P. now owns 1,218,352 shares of the medical equipment provider’s stock valued at $82,227,000 after buying an additional 1,113,330 shares in the last quarter. 94.73% of the stock is owned by institutional investors.

About Hologic

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.